Clinical Research Directory

Inclusion Criteria: * ≥ 18 years of age * Patient diagnosed with CD for more than 6 months with histological confirmation available in his medical record. * Indication for MRE based on routine clinical practice validated by the treating physician * Any CD treatment will be authorized, such as biologicals (infliximab, adalimumab, vedolizumab, ustekinumab…), or immunomodulators (azathioprine, 6-mercaptopurine, methotrexate…). * The subjects sign and date a written, informed consent form and any required privacy authorization prior to the initiation of the study. * A subject can be enrolled into the study only if the grade of TH (assessed by the LRP) corresponding to the subject is not already fulfilled. Exclusion Criteria: * Pregnancy during the study * People unable to give consent (because of their physical or mental state) * Absence of written consent * Ulcerative colitis or unclassified IBD * Specific postsurgical settings: ileoanal anastomosis, ileostomy or colostomy. * Less than 3 evaluable ileocolic segments or more than 3 resected ileocolonic segments (not counting ileocecal valve) * Severe obstructive symptoms * Symptomatic intra-abdominal abscess * Contraindication for MRI * Isolated perianal disease without luminal location * MRE images of poor quality, based on previously defined criteria